Association of IgA Anti-ß2 Glycoprotein I with Clinical and Laboratory Manifestations of Systemic Lupus Erythematosus

REFERENCES

1. 1.↵
   1. Fanopoulos D,
   2. Teodorescu MR,
   3. Varga J,
   4. Teodorescu M

   . High frequency of abnormal levels of IgA anti-ß₂-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome. J Rheumatol 1998;25:675–80.

   OpenUrlPubMed
2. 2.↵
   1. Tsutsumi A,
   2. Matsuura E,
   3. Ichikawa K,
   4. Fujisaku A,
   5. Mukai M,
   6. Koike T

   . IgA class anti-ß₂-glycoprotein I in patients with systemic lupus erythematosus. J Rheumatol 1998;25:74–8.

   OpenUrlPubMed
3. 3.↵
   1. Cucurull E,
   2. Gharavi AE,
   3. Diri E,
   4. Mendez E,
   5. Kapoor D,
   6. Espinoza LR

   . IgA anticardiolipin and anti-ß₂-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci 1999;318:55–60.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Danowski A,
   2. Kickler T,
   3. Petri M

   . Anti-ß₂-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 2006;33:1775–9.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Lee S,
   2. Cho M,
   3. Joo Y,
   4. Kim W,
   5. Hong Y,
   6. Min J,
   7. et al.

   Isotypes of anti-ß₂-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus. J Rheumatol 2001;28:520–4.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Lakos G,
   2. Kiss E,
   3. Regeczy P,
   4. Tarján P,
   5. Soltész P,
   6. Zeher M,
   7. et al.

   Isotype distribution and clinical relevance of anti-ß₂-glycoprotein I antibodies: importance of IgA isotype. Clin Exp Immunol 1999;117:574–9.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Diri E,
   2. Cucurull E,
   3. Gharavi AE,
   4. Kapoor D,
   5. Mendez EA,
   6. Scopelitis E,
   7. et al.

   Antiphospholipid (Hughes’) syndrome in African-Americans: IgA aCL and anti-ß₂-glycoprotein I is the most frequent isotype. Lupus 1999;9:33–41.

   OpenUrlCrossRef
8. 8.↵
   1. Tan EM,
   2. Cohen AS,
   3. Fries JF,
   4. Masi AT,
   5. McShane DJ,
   6. Rothfield NF,
   7. et al.

   The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Hochberg MC

   . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Petri M,
    2. Rheinschmidt M,
    3. Whiting-O’Keefe Q,
    4. Hellmann D,
    5. Corash L

    . The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and cardiolipin antibody level. Ann Intern Med 1987;106:524–31.

    OpenUrlPubMed
11. 11.↵
    1. Somers E,
    2. Magder LS,
    3. Petri M

    . Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with SLE. J Rheumatol 2002;29:2531–6.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Petri M,
    2. Kim MY,
    3. Kalunian KC,
    4. Grossman J,
    5. Hahn BH,
    6. Sammaritano LR,
    7. et al.

    Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550–8.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Bombardier C,
    2. Gladman DD,
    3. Chang CH,
    4. Urowitz MB,
    5. the Committee on Prognosis Studies in SLE

    . Development of the Disease Activity Index: the SLEDAI. Arthritis Rheum 1992;35:630–40.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Gladman D,
    2. Ginzler E,
    3. Goldsmith C,
    4. Fortin P,
    5. Liang M,
    6. Urowitz M,
    7. et al.

    Systemic Lupus International Collaborative Clinics: Development of a damage index in systemic lupus erythematosus. J Rheumatol 1992;29:1820–1.

    OpenUrl
15. 15.↵
    1. Bertolaccini ML,
    2. Atsumi T,
    3. Contreras AE,
    4. Khamashta MA,
    5. Hughes GRV

    . The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 2001;28:2637–43.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Carmo-Pereira S,
    2. Bertolaccini ML,
    3. Escudero-Contreras A,
    4. Khamashta MA

    . Value of IgA anticardiolipin and anti-ß₂-glycoprotein I antibody testing in patients with pregnancy morbidity. Ann Rheum Dis 2003;62:540–3.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Samarkos M,
    2. Davies KA,
    3. Gordon C,
    4. Loizou S

    . Clinical significance of IgA anticardiolipin and anti-ß₂-gpi antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol 2006;25:199–204.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Cervera R,
    2. Piette J,
    3. Font J,
    4. Khamashta MA,
    5. Shoenfeld Y,
    6. Camps MT,
    7. et al.

    Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002;46:1019–27.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Asherson RA,
    2. Cervera R

    . Pulmonary hypertension, antiphospholipid antibodies, and syndromes. Clin Rev Allergy Immunol 2007;32:153–8.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Ramos-Casals M,
    2. Nardi N,
    3. Brito-Zeron P,
    4. Aguilo S,
    5. Gil V,
    6. Delgado G,
    7. et al.

    Atypical autoantibodies in patients with primary Sjogren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 2006;35:312–21.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Fauchais AL,
    2. Lambert M,
    3. Launay D,
    4. Michon-Pasturel U,
    5. Queyrel V,
    6. Nguyen N,
    7. et al.

    Antiphospholipid antibodies in primary Sjogren’s syndrome: prevalence and clinical significance in a series of 74 patients. Lupus 2004:13:245–8.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Cervera R,
    2. Garcia-Carrasco M,
    3. Font J,
    4. Ramos M,
    5. Reverter JC,
    6. Muñoz FJ,
    7. et al.

    Antiphospholipid antibodies in primary Sjogren’s syndrome: prevalence and clinical significance in a series of 80 patients. Clin Exp Rheumatol 1997;15:361–5.

    OpenUrlPubMed
23. 23.↵
    1. Merkel PA,
    2. Chang Y,
    3. Pierangeli SS,
    4. Convery K,
    5. Harris EN,
    6. Polisson RP

    . The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996;101:576–83.

    OpenUrlCrossRefPubMed